Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee

Summary The management of primary hypothyroidism with levothyroxine (L‐T4) is simple, effective and safe, and most patients report improved well‐being on initiation of treatment. However, a proportion of individuals continue to suffer with symptoms despite achieving adequate biochemical correction....

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Clinical endocrinology (Oxford) Ročník 84; číslo 6; s. 799 - 808
Hlavní autori: Okosieme, Onyebuchi, Gilbert, Jackie, Abraham, Prakash, Boelaert, Kristien, Dayan, Colin, Gurnell, Mark, Leese, Graham, McCabe, Christopher, Perros, Petros, Smith, Vicki, Williams, Graham, Vanderpump, Mark
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England Blackwell Publishing Ltd 01.06.2016
Wiley Subscription Services, Inc
Predmet:
Disease Management
Drug Therapy, Combination
Endocrinology
Humans
Hypothyroidism
Hypothyroidism - drug therapy
Practice Guidelines as Topic - standards
Thyroid
Thyroid gland
Thyroxine
Thyroxine - therapeutic use
Triiodothyronine
Triiodothyronine - therapeutic use
Well being
ISSN:0300-0664, 1365-2265, 1365-2265
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Summary The management of primary hypothyroidism with levothyroxine (L‐T4) is simple, effective and safe, and most patients report improved well‐being on initiation of treatment. However, a proportion of individuals continue to suffer with symptoms despite achieving adequate biochemical correction. The management of such individuals has been the subject of controversy and of considerable public interest. The American Thyroid Association (ATA) and the European Thyroid Association (ETA) have recently published guidelines on the diagnosis and management of hypothyroidism. These guidelines have been based on extensive reviews of the medical literature and include sections on the role of combination therapy with L‐T4 and liothyronine (L‐T3) in individuals who are persistently dissatisfied with L‐T4 therapy. This position statement by the British Thyroid Association (BTA) summarises the key points in these guidelines and makes recommendations on the management of primary hypothyroidism based on the current literature, review of the published positions of the ETA and ATA, and in line with best principles of good medical practice. The statement is endorsed by the Association of Clinical Biochemistry, (ACB), British Thyroid Foundation, (BTF), Royal College of Physicians (RCP) and Society for Endocrinology (SFE).
Bibliografia:istex:1F768538FBB0634FDF9CA1B4B86AB87AB4DDA16C
ArticleID:CEN12824
ark:/67375/WNG-XBDWMTNJ-W
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0300-0664
1365-2265
1365-2265
DOI:10.1111/cen.12824